Related Experiment Videos
Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer
Ying Chen1, Lu Lu1, Bing Feng1
1Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, PR China.
Abstract:
Non-small cell lung cancer (NSCLC) remains a major health problem that patients suffer from around the world. The epithelial to mesenchymal transition (EMT) has attractive roles in increasing malignant potential and reducing sensitivity to conventional therapeutics in NSCLC cells. Meanwhile, it is now evident that non-coding RNAs (ncRNAs), primarily microRNAs and long non-coding RNAs contribute to tumorigenesis partially via regulating EMT. This article briefly summarizes current researches about EMT-related ncRNAs in NSCLC and discusses their crucial roles in the complex regulatory network. Also, the authors will show the evidence that ncRNAs not only contribute to cancer cells migration and invasion, but also take charge of the resistance of chemotherapy, radiotherapy and EGFR-TIKs. Then, we will further discuss the potential of inhibition of EMT via manipulating relevant ncRNAs to change our current treatment of NSCLC patients.
Insights
Non-small cell lung cancer (NSCLC) progression is linked to epithelial to mesenchymal transition (EMT). Non-coding RNAs (ncRNAs) regulate EMT, influencing NSCLC malignancy and treatment resistance.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) is a global health challenge.
- Epithelial to mesenchymal transition (EMT) increases NSCLC malignancy and therapeutic resistance.
- Non-coding RNAs (ncRNAs), including microRNAs and long non-coding RNAs, are implicated in NSCLC tumorigenesis via EMT regulation.
Purpose of the Study:
- To summarize research on EMT-related ncRNAs in NSCLC.
- To discuss the roles of ncRNAs in NSCLC's complex regulatory network.
- To explore ncRNAs' involvement in cancer cell migration, invasion, and resistance to therapies like chemotherapy, radiotherapy, and EGFR-TKI.
Main Methods:
- Literature review of current research on EMT-related ncRNAs in NSCLC.
- Analysis of the regulatory network involving ncRNAs and EMT.
- Examination of evidence linking ncRNAs to specific cancer behaviors and treatment resistance.
Main Results:
- ncRNAs play crucial roles in regulating EMT in NSCLC.
- ncRNAs contribute to cancer cell migration and invasion.
- ncRNAs are involved in resistance to chemotherapy, radiotherapy, and EGFR-TKI treatments.
Conclusions:
- EMT-related ncRNAs are key players in NSCLC pathogenesis.
- Targeting ncRNAs to inhibit EMT presents a potential therapeutic strategy for NSCLC.
- Manipulating ncRNAs could offer novel treatment approaches for NSCLC patients.